Each year, thousands of serious injuries, including deaths, linked to dangerous drugs are reported to the FDA. When a drug manufacturer's negligence caused these injuries, we have a proven track record of standing up for the people victimized by these dangerous drugs.
We are currently investigating claims for those who have a history of taking Zantac® or generic ranitidine and were diagnosed with cancer of the stomach, breast, bladder, small intestine, colon/rectum, esophagus, prostate, pancreas, or kidneys, or with leukemia, Non-Hodgkin’s lymphoma, or multiple myeloma. On September 13, 2019, the U.S. Food and Drug Administration (FDA) released a statement alerting patients and health care professionals about the discovery of the presence of a contaminant, the human carcinogen N-nitrosodimethylamine (NDMA) in samples of ranitidine commonly known as the brand-name drug Zantac®. On April 1, 2020, The U.S. Food and Drug Administration announced it was requesting that manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
We are currently investigating claims for those who have taken Valsartan after January 1st of 2015 and subsequently been diagnosed with liver cancer, stomach cancer, colorectal cancer or suffered an acute liver injury requiring hospitalization. In 2018 the FDA announced a voluntary recall of several medications that contain valsartan. The recall was initiated after the discovery of the presence of a contaminant N-nitrosodimethylamine (NDMA) in the recalled drugs. NDMA is classified as a probable human carcinogen which means that it is more likely than not to cause cancer in humans.
We are currently investigating claims for those who have suffered a cardiac event requiring hospitalization while taking Uloric. Uloric (febuxostat) is a medication prescribed to lower uric acid levels in individuals with gout. Gout is a type of arthritis that occurs when a naturally occurring substance in the body known as uric acid builds up, causing sudden attacks of redness, swelling, and pain in joints. Approved for sale by the FDA in February 2009, Uloric is intended to lower uric acid levels in the bloodstream.
You made a difference in my life. I am forever grateful.
- E.S.